<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.ajmc.com/view/cystatin-c-creatinine-egfr-gap-flags-higher-mortality-hf-risk</loc>
      <lastmod>2026-11-19T21:32:44.458Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T21:32:44.458Z</news:publication_date>
        <news:title><![CDATA[Cystatin C, Creatinine eGFR Gap Flags Higher Mortality, HF Risk]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/owning-the-medication-list-across-care-transitions</loc>
      <lastmod>2026-11-19T21:01:29.787Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T21:01:29.787Z</news:publication_date>
        <news:title><![CDATA[Owning the Medication List Across Care Transitions]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/cefiderocol-holds-activity-against-resistant-pseudomonas-in-vap</loc>
      <lastmod>2026-11-19T19:04:10.354Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T19:04:10.354Z</news:publication_date>
        <news:title><![CDATA[Cefiderocol Holds Activity Against Resistant Pseudomonas in VAP]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/iron-deficiency-in-heart-failure-is-a-workflow-problem-faculty-say</loc>
      <lastmod>2026-11-19T18:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Iron Deficiency in Heart Failure Is a Workflow Problem, Faculty Say]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/fda-approves-first-sirna-therapy-for-achr-positive-myasthenia-gravis</loc>
      <lastmod>2026-11-19T16:57:30.674Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T16:57:30.674Z</news:publication_date>
        <news:title><![CDATA[FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/local-vs-central-testing-what-it-means-for-ensitrelvir-covid-19-pep</loc>
      <lastmod>2026-11-19T16:57:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T16:57:00Z</news:publication_date>
        <news:title><![CDATA[Local vs Central Testing: What It Means for Ensitrelvir COVID-19 PEP]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/most-patients-with-psoriasis-screened-positive-for-psa-at-one-dermatology-clinic</loc>
      <lastmod>2026-11-19T16:45:36.946Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T16:45:36.946Z</news:publication_date>
        <news:title><![CDATA[Most Patients With Psoriasis Screened Positive for PsA at One Dermatology Clinic]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/obesity-care-ownership-shifts-to-specialties-that-win-coverage</loc>
      <lastmod>2026-11-19T15:54:42.578Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T15:54:42.578Z</news:publication_date>
        <news:title><![CDATA[Obesity Care Ownership Shifts to Specialties That Win Coverage]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/new-employer-guide-maps-diabetes-prevention-care-resources</loc>
      <lastmod>2026-11-19T15:28:44.377Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T15:28:44.377Z</news:publication_date>
        <news:title><![CDATA[New Employer Guide Maps Diabetes Prevention, Care Resources]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/transitioning-to-all-oral-aml-therapy-prior-authorization-pearls-and-copay-timing</loc>
      <lastmod>2026-11-19T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Transitioning to All-Oral AML Therapy: Prior Authorization Pearls and Copay Timing]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/securing-access-to-oral-aml-therapy-formularies-prior-authorization-and-copays</loc>
      <lastmod>2026-11-19T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Securing Access to Oral AML Therapy: Formularies, Prior Authorization, and Copays]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/ensitrelvir-pep-lowers-viral-load-in-covid-19-breakthrough-infections</loc>
      <lastmod>2026-11-18T22:08:38.403Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T22:08:38.403Z</news:publication_date>
        <news:title><![CDATA[Ensitrelvir PEP Lowers Viral Load in COVID-19 Breakthrough Infections]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/camden-residents-weigh-in-on-psychedelic-therapy-jeff-brown</loc>
      <lastmod>2026-11-18T21:52:22.693Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T21:52:22.693Z</news:publication_date>
        <news:title><![CDATA[Camden Residents Weigh In on Psychedelic Therapy: Jeff Brown]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/low-crc-incidence-found-after-endoscopic-mucosal-resection</loc>
      <lastmod>2026-11-18T21:10:21.859Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T21:10:21.859Z</news:publication_date>
        <news:title><![CDATA[Low CRC Incidence Found After Endoscopic Mucosal Resection]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/fda-approves-obinutuzumab-as-first-therapy-for-membranous-nephropathy</loc>
      <lastmod>2026-11-18T21:07:57.700Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T21:07:57.700Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Obinutuzumab as First Therapy for Membranous Nephropathy]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/complicated-uti-care-strained-by-unclear-goals-access-gaps</loc>
      <lastmod>2026-11-18T20:39:20.346Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T20:39:20.346Z</news:publication_date>
        <news:title><![CDATA[Complicated UTI Care Strained by Unclear Goals, Access Gaps]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/aficamten-reduces-lv-mass-wall-thickness-in-nonobstructive-hcm</loc>
      <lastmod>2026-11-18T19:37:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T19:37:00Z</news:publication_date>
        <news:title><![CDATA[Aficamten Reduces LV Mass, Wall Thickness in Nonobstructive HCM]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/fda-approves-oral-giredestrant-regimen-for-esr1-mutated-breast-cancer</loc>
      <lastmod>2026-11-18T17:51:13.156Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T17:51:13.156Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/sending-the-call-for-fixed-duration-bispecific-trials-in-myeloma</loc>
      <lastmod>2026-11-18T17:37:46.308Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T17:37:46.308Z</news:publication_date>
        <news:title><![CDATA[Sending the Call for Fixed-Duration Bispecific Trials in Myeloma]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/hepatitis-b-screening-gaps-persist-as-functional-cure-option-arrives</loc>
      <lastmod>2026-11-18T17:01:12.795Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T17:01:12.795Z</news:publication_date>
        <news:title><![CDATA[Hepatitis B Screening Gaps Persist as Functional Cure Option Arrives]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/dazodalibep-shows-phase-3-benefit-in-sj-gren-disease</loc>
      <lastmod>2026-11-18T16:01:41.621Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T16:01:41.621Z</news:publication_date>
        <news:title><![CDATA[Dazodalibep Shows Phase 3 Benefit in Sjögren Disease ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/iga-nephropathy-fsgs-care-needs-coordinators-not-just-new-drugs</loc>
      <lastmod>2026-11-18T15:51:13.252Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T15:51:13.252Z</news:publication_date>
        <news:title><![CDATA[IgA Nephropathy, FSGS Care Needs Coordinators, Not Just New Drugs]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/obstructive-hcm-care-hinges-on-teams-pharmacy-and-drug-access</loc>
      <lastmod>2026-11-18T14:36:55.816Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:36:55.816Z</news:publication_date>
        <news:title><![CDATA[Obstructive HCM Care Hinges on Teams, Pharmacy, and Drug Access ]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/fda-approves-secukinumab-as-first-anti-il-17-biologic-for-pmr</loc>
      <lastmod>2026-11-18T14:30:01.007Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:30:01.007Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMR]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/mash-drugs-raise-urgency-for-earlier-diagnosis-rohit-loomba-md</loc>
      <lastmod>2026-11-18T14:13:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T14:13:00Z</news:publication_date>
        <news:title><![CDATA[MASH Drugs Raise Urgency for Earlier Diagnosis: Rohit Loomba, MD]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/patient-factors-and-access-barriers-in-extensive-stage-sclc</loc>
      <lastmod>2026-11-18T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:05:00Z</news:publication_date>
        <news:title><![CDATA[Patient Factors and Access Barriers in Extensive-Stage SCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/aatd-pipeline-replacement-liver-directed-rna-and-gene-therapy-approaches</loc>
      <lastmod>2026-11-18T13:05:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:05:00Z</news:publication_date>
        <news:title><![CDATA[AATD Pipeline: Replacement, Liver-Directed, RNA, and Gene Therapy Approaches]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/switching-aatd-patients-to-every-3-4-week-infusions-logistics-and-cost</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Switching AATD Patients to Every 3-4 Week Infusions: Logistics and Cost]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/maintenance-therapy-options-in-extensive-stage-sclc</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Maintenance Therapy Options in Extensive-Stage SCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.ajmc.com/view/atopic-dermatitis-escalation-stalls-on-payer-rules-thin-tracking</loc>
      <lastmod>2026-11-17T21:46:17.823Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>AJMC</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T21:46:17.823Z</news:publication_date>
        <news:title><![CDATA[Atopic Dermatitis Escalation Stalls on Payer Rules, Thin Tracking]]></news:title>
      </news:news>
	</url></urlset>